Kardigan builds computational and clinical infrastructure for cardiovascular drug discovery. The company's Cardiac Intelligence platform applies data-driven methods to identify and develop targeted treatments for individual patients, moving beyond one-size-fits-all cardiology. It runs a parallel pipeline of late-stage clinical candidates, each aimed at specific disease mechanisms rather than broad symptomatic relief.
The founding team - Tassos Gianakakos, Jay Edelberg, and Bob McDowell - previously held senior roles at MyoKardia, the biotech known for developing mavacamten for hypertrophic cardiomyopathy before its acquisition by Bristol Myers Squibb in 2020 for $13.1 billion. That experience in precision cardiovascular therapeutics informs Kardigan's approach: stack multiple targeted assets rather than bet on a single molecule. The company operates out of South San Francisco and Princeton, New Jersey, within established biopharma clusters.
Cardiovascular disease remains the world's leading cause of death. Kardigan's stated mission is to make it preventable and curable - a goal that requires both clinical validation at scale and the engineering systems to match treatments to disease subtypes. The security and integrity of patient data, proprietary compound libraries, and platform intelligence are operational prerequisites, not afterthoughts.
